【摘要】 目的比较氯米帕明和米氮平治疗抑郁症的疗效。方法80例门诊抑郁症患者随机分为氯米帕明和米氮平治疗组,疗程8周,用汉密尔顿抑郁量表(HAMD),临床疗效总评量表(CGI)和副反应症状量表(TESS)在治疗前及治疗后第2、4、8周末行评定。结果治疗8周后氯米帕明组和米氮平组HAMD减分率分别为71．89%和71．74%,两组治疗前、后比较差异均有显著性(P＜0．01),但两组间比较差异无显著性(P＞0．05)。氯米帕明副反应发生率33．25%,米氮平22．21%两组间比较差异有显著性(P＜0．05)。结论米氮平治疗抑郁症疗效与氯米帕明相当,副反应轻。更多还原

【Abstract】 Objective:To compare the efficacy and safety of chlorimipramine and mirtazapine in the treatment of depression.Methods:80 outpatients with a diagnosis of depression were randomly assigned to chlorimipramine or mirtazapine groups for 8 weeks treatment.Efficacy and safety were assessed by HAMD (Hamilton Rating Scale for depression),CGI(Clinical Global Impression rating scale)and TESS.Assessments were performed at weeks 0,2,4 and 8.Results:The responses by wk 8(decrease in HAMD scores for 71.89% and 71.74% from baseline respectively)were observed in patients treated with chlorimipramine and the Mirtazapine.Both medication groups showed a significant improvement over the 8 weeks of treatment(P＜0. 05).There was no statistically significant difference between the mean +/-SEM HAMD scores of two groups (P＞0.05).The rates of side effects on chlorimipramine and mirtazapine were greatly different(P＜0.05). Conclusion:Mirtazapine is as effective as chlorimipramine in the treatment of depression with less side effects.更多还原